Ehring et al Ramiprilat and Stunned Myocardium 1369 potential are largely different in buffer-and in bloodperfused systems.
Thus, in a first set of experiments, we sought to determine whether bradykinin is also involved in the beneficial effect of the ACE inhibitor ramiprilat during regional myocardial ischemia and reperfusion in vivo. Open-chest anesthetized dogs therefore received ramiprilat with or without the bradykinin B2 receptor antagonist HOE 140.
Stimulation of bradykinin B2 receptors results in an enhanced formation of prostacyclin and nitric oxide in cultured human and bovine endothelial cells.514 Both prostaglandins'5-'8 and nitric oxide19 have been demonstrated to attenuate ischemia/reperfusion injury. Also, the involvement of prostaglandins in the beneficial effects of ACE inhibitors on stunned myocardium has previously been demonstrated in vitro'4 and in vivo. 8 In isolated, buffer-perfused rat hearts, the cyclooxygenase inhibitor indomethacin completely abolished the beneficial effect of captopril on the functional recovery of stunned myocardium,' whereas in a similar model indomethacin only partially prevented the enhancement of functional recovery of stunned myocardium induced by ramipril. 4 Also, in open-chest dogs, indomethacin only partially reversed the improvement of functional recovery of stunned myocardium induced by enalaprilat.8 These studies, however, did not address a potential contribution of nitric oxide to the beneficial effects of ACE inhibitors. In two other studies in isolated, bufferperfused rat5 and guinea pig20 hearts, however, the beneficial effect of ramiprilat and bradykinin on ventricular function during reperfusion was completely abolished by the nitric oxide synthase inhibitor NG-nitro-Larginine (L-NNA). In these studies, however, the contribution of prostaglandins to the observed beneficial effect was not investigated.
The detailed contribution of both the prostaglandin and the nitric oxide pathways was therefore determined in a second set of experiments. In these experiments, open-chest dogs received the cyclooxygenase inhibitor indomethacin with or without ramiprilat or the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) with or without ramiprilat. Methods
The dogs were handled according to the guidelines of the American Physiological Society, and the protocol was approved by the bioethical committee of the district of Dusseldorf, FRG. Experimental Preparation Fifty-six mongrel dogs (22 to 37 kg body wt) were anesthetized with an initial bolus of sodium thiamylal (15 mg/kg IV). After endotracheal intubation, anesthesia was maintained by ventilation with 1.4 vol% enflurane in a nitrous oxide/oxygen mixture with a respirator (Spiromat 650, Drager Werke AG). Arterial blood gases and hematocrit were monitored regularly (ABL 3, Radiometer) and maintained within the normal range. Body temperature is a major factor determining the functional recovery of stunned myocardium.21 Therefore, esophageal temperature was measured periodically, and body temperature was maintained between 37°C and 38°C with a heating pad. Left ventricular and aortic pressures were measured with catheter-tip manometers (PC 350, Millar) inserted via the right and left brachial arteries. Heart rate and left ventricular dP/dt were derived from the left ventricular pressure signal. A Teflon catheter (2.0-mm inner diameter) was inserted via the right femoral artery into the upper descending aorta for blood withdrawal. A balloon catheter (Fogarty occlusion catheter 8/22F, Baxter GmbH) was inserted via the left femoral artery, and the balloon was placed in the descending aorta approximately 10 cm distal to the ostium of the withdrawal catheter. Inflation of the balloon served to compensate for potential decreases in mean aortic pressure. A left thoracotomy was performed in the fifth intercostal space. The pericardium was opened and sutured to cradle the heart. Ultrasonic crystals were implanted in the anterior left ventricular wall (control area) perfused by the left anterior descending coronary artery (LAD) and in the posterolateral wall perfused by the left circumflex coronary artery (LCx) for measurement of regional myocardial wall thickness (Sonomicrometer 120, Triton Technologies Inc) by standard techniques. 22 The LCx was dissected free for about 2 cm proximal to its first side branch for placement of an electromagnetic flow probe and a mechanical occluder distal to the flow probe. Distal to the occluder, a 27-gauge cannula (Microlance, Becton-Dickinson Ltd) was inserted into the LCx for intracoronary drug infusion. A Teflon catheter (2-mm inner diameter) was placed into the left atrium through the atrial appendage for later microsphere injection.
Measurement of Regional Myocardial Blood Flow
Regional myocardial blood flow was determined with a technique developed in our laboratory23 using 15 -,m microspheres dyed with one of five different colors (Dye-Trak, Triton Technologies Inc). For each measurement, approximately 3x106 to 11x106 microspheres suspended in 6 mL saline (containing 0.02% Tween 80) were injected into the left atrium. The number of microspheres was adjusted with respect to the specific absorbance of the respective dye, ie, 7x 106 to 1Ox 106 for white, 6x 106 to 11x 106 for yellow, 3x 106 to 6x 106 for red, 4x106 to 8x106 for blue, and 7X106 to 9x106 for violet microspheres. Each microsphere injection was followed by a flush of 6 mL saline. The withdrawal of arterial reference blood samples was started 30 seconds before injection of the microspheres and continued for 150 seconds at a rate of 5.3 mL/min (Withdrawal Pump model 901A, Harvard Apparatus).
Study Protocol
After the instrumentation was complete, control measurements of systemic hemodynamics and regional myocardial blood flow and function were performed. All dogs were then subjected to a 15-minute LCx occlusion. At 10 minutes of LCx occlusion, systemic hemodynamics and regional myocardial blood flow and function were measured again. Measurements of systemic hemodynamics and regional myocardial blood flow and function were repeated at 4 hours after release of the LCx occlusion. Systemic hemodynamics and regional myocardial function were also measured at 1, 2, and 3 hours of reperfusion. In a first set of experiments, 32 dogs were randomly assigned to four groups of 8 dogs each.
Group 1 was the placebo group. In this group of dogs, saline (1 mL/min) was infused into the LCx throughout the experimental protocol (Fig 1A) .
Group 2 received ramiprilat. After control measurements, ramiprilat (20 jig/kg dissolved in 20 mL saline infused over 5 minutes; Astra Chemicals) was infused intravenously. The drug-induced decrease in mean aortic pressure was compensated for by inflation of the intra-aortic balloon, and measurements of systemic hemodynamics and regional myocardial blood flow and function were repeated. Saline (1 mL/min) was infused into the LCx throughout the experimental protocol. Fifteen minutes after the end of the ramiprilat infusion, the LCx was occluded (Fig 1A) . (Table 1) . With ongoing HOE 140 infusion, measurements of systemic hemodynamics and regional myocardial blood flow and function were then repeated. Fifty minutes after the start of the HOE 140 infusion, the LCx was occluded (Fig lA) .
Group 4 received HOE 140 plus ramiprilat. The experimental procedure was similar to that in group 3. After an effective blockade of bradykinin B2 receptors with HOE 140 was established, ramiprilat was infused intravenously as described above. Measurements of systemic hemodynamics and regional myocardial blood flow and function were repeated when mean aortic pressure was matched to values before ramiprilat administration. Sixty-five minutes after the start of the HOE 140 infusion and 15 minutes after the end of the ramiprilat infusion, the LCx was occluded (Fig lA) .
Protocol 2: Role of Prostaglandins and Nitric Oxide in the Effect of Ramiprilat
In a second set of experiments, 24 dogs were randomly assigned to four groups of 6 dogs each.
Group 5 received indomethacin. After control measurements, the cyclooxygenase inhibitor indomethacin (10 mg/kg dissolved in 50 mL buffer containing 0.5 mol/L Na2HPO4 and 0.5 mol/L NaH2PO4, infused over 45 minutes; Sigma Chemicals) was infused intravenously. Infusion of the pure solvent did not result in any changes of the measured parameters. Indomethacin was infused intravenously, since in preliminary experiments we were unable to achieve a sufficient inhibition of the coronary dilator response to intracoronary arachidonic acid with an intracoronary infusion of indomethacin. The effective and persistent inhibition of the cyclooxygenase by intravenous indomethacin was tested under control conditions and at the end of the experiments by intracoronary infusion of arachidonic acid [5 . g/(kg * mL) of the sodium salt dissolved in saline, 1 mL infused over 30 seconds; Sigmal (Table 1) . When a hemodynamic steady state in response to indomethacin was reached, measurements of systemic hemodynamics and regional myocardial blood flow and function were repeated. Ten minutes after the end of the indomethacin infusion, the LCx was occluded (Fig 1B) .
Group 6 received indomethacin plus ramiprilat. The experimental procedure was similar to that in group 5. After infusion of indomethacin, ramiprilat was infused intravenously as described above. Additional measurements of systemic hemodynamics and regional myocardial blood flow and function were performed when mean aortic pressure was matched to values before ramiprilat administration. Twenty-five minutes after the end of the indomethacin infusion and 15 minutes after the end of the ramiprilat infusion, the LCx was occluded (Fig 1B) .
Group 7 received L-NAME. After control measurements, the nitric oxide synthase inhibitor L-NAME (20 mg/kg dissolved in 20 mL saline infused over 45 minutes; Sigma) was infused intravenously. An effective and persistent inhibition of the nitric oxide synthase was tested by intracoronary infusion of acetylcholine [0.5 ng/(kg . mL) dissolved in saline, 1 mL infused over 30 seconds; Sigmal and bradykinin [2 ng/ (kg . mL), 1 mL infused over 30 seconds; Sigmal under control conditions and at the end of the experiments (Table 1) . When a hemodynamic steady state in response to L-NAME was reached, measurements of systemic hemodynamics and regional myocardial blood flow and function were repeated. Ten minutes after the end of the L-NAME infusion, the LCx was occluded (Fig 1B) .
Group 8 received L-NAME plus ramiprilat. The experimental procedure was similar to that in group 7. After L-NAME infusion, ramiprilat was infused intravenously as described above. Additional measurements of systemic hemodynamics and regional myocardial blood flow and function were performed when mean aortic pressure was matched to values before ramiprilat administration. Twenty-five minutes after the end of the L-NAME infusion and 15 minutes after the end of the ramiprilat infusion, the LCx was occluded (Fig 1B) .
Data Analysis
Systemic hemodynamics and myocardial wall thickness of the anterior and the posterior regions were continuously monitored on an eight-channel forced-ink chart recorder (model MK 200 A, Gould Inc) and stored on magnetic tape (TEAC XR-7000, Carston Electronics). Data were digitized in 5-millisecond intervals by use of a software package (CORDAT II, Triton Technologies Inc) developed in our laboratory. 24 Fifteen sequential beats were averaged for each intervention to account for respiratory variations. Regional myocardial function was determined as systolic wall thickening (systolic wall excursion in percent of end-diastolic wall thickness). End diastole was defined as the zero crossing point of the first derivative of left ventricular pressure (dP/dt) before its rapid upstroke, and regional end systole was defined as the time of maximum wall thickness within 20 milliseconds before peak negative dP/dt.25 End-diastolic and end-systolic wall thickness were normalized to an end-diastolic wall thickness of 10 mm under control conditions to account for interindividual differences.26 LCx arterial inflow and regional myocardial blood flow were normalized to 1 g of perfused myocardial tissue.
Postmortem Analysis
At the end of each experiment, the perfusion territory of the LCx was delineated by intracoronary injection of methylene blue immediately before the dog was killed by intracardiac injection of potassium chloride. The perfusion territory of the LCx was cut out and weighed. The myocardial regions containing the crystals of the anterior and the posterior regions were cut out, and the subendocardial position of the inner crystal was verified. These two blocks of tissue (approximately 9 g each) were cut in an array of 3x3 samples per perfusion territory. Regional myocardial blood flow in the subendocardium, midmyocardium, and subepicardium was separately determined. The average weight of samples was 0.34±0.15 g.
The blood flow values in the nine samples per layer were averaged for each animal.
After extraction of the dye, the color spectra of each myocardial and arterial reference withdrawal sample were measured with a spectrophotometer (model 8452A, HewlettPackard Co). Separation of overlapping spectra was performed by a matrix inversion technique. 23 Regional myocardial blood flow per sample, corrected for wet weight, was calculated according to the equation: Regional myocardial blood flow equals reference withdrawal rate times absorbance per sample divided by absorbance in the arterial withdrawal. The absorbance was determined as specific absorbance for each color.
Statistical Analysis
Data are reported as mean+SD. Three dogs of group 1; 1 dog of group 2; 5 dogs of group 3; 7 dogs of group 4; 3 dogs each of groups 5, 6, and 7; and 4 dogs of group 8 went into ventricular fibrillation immediately upon reperfusion. However, in each instance the dogs were immediately resuscitated by DC countershock (25 to 50 Ws) and thereafter did not differ in any variable from the remaining dogs in the respective groups that did not undergo ventricular fibrillation. Statistical analysis was performed with SYSTAT software (Systat Inc). Changes in systemic hemodynamics and regional myocardial blood flow and dimensions were estimated by two-way ANOVA for repeated measurements, accounting for the different points of time throughout the experiments and the different groups of dogs. This analysis was performed separately for groups 1 through 4, groups 5 and 6, and groups 7 and 8. The weights of the LCx perfusion territories of groups 1 through 4, groups 5 and 6, and groups 7 and 8 were compared by one-way ANOVA. When a significant overall effect was detected, Tukey's t tests were performed to compare single mean values. When multiple comparisons were performed, P values were adjusted according to Bonferroni. A value of P<.05 indicated a significant difference. Since posterior systolic wall thickening was the key parameter indicating the functional myocardial recovery during reperfusion, an additional, more sensitive analysis was performed on this parameter by use of linear regression analysis of posterior systolic wall thickening over time (from occlusion to 4 hours of reperfusion). These linear regressions were compared by ANCOVA, again separately for groups 1 through 4, 5 and 6, and 7 and 8. Systemic Hemodynamics Heart rate, peak left ventricular pressure, mean aortic pressure, and peak left ventricular dP/dt remained constant throughout the experimental protocol within each group of dogs and were not different between groups 1 through 4 ( Table 2 ). End-diastolic left ventricular pressure tended to increase during LCx occlusion, this increase being significant only in group 4. Upon reperfusion, end-diastolic left ventricular pressure returned to baseline values and remained constant during the remaining reperfusion period (Table 2) .
Results

Regional Myocardial Blood Flow
Anterior myocardial blood flow remained constant throughout the experimental protocol within each group of dogs and was not different between groups 1 through 4 (Table 3) .
During control conditions, posterior myocardial blood flow was not different between groups 1 through 4 ( Table 3 ). Posterior myocardial blood flow did not change in response to administration of ramiprilat (group 2), HOE 140 (group 3), and the combination of HOE 140 and ramiprilat (group 4). During LCx occlusion, posterior myocardial blood flow was reduced to the same extent in all groups of dogs (Table 3) . At 4 hours of reperfusion, posterior myocardial blood flow was somewhat lower than during preischemic control conditions in all groups of dogs but was not different between groups 1 through 4 (Table 3) .
Regional Myocardial Function
Anterior systolic wall thickening did not change significantly throughout the experimental protocol within each group of dogs and was not different between groups 1 through 4 ( Table 4) . During control conditions, posterior systolic wall thickening was not different between groups 1 through 4 ( Fig 4, Table 4 ). Posterior systolic wall thickening did not change in response to ramiprilat (group 2), HOE 140 (group 3), and the combination of HOE 140 and ramiprilat (group 4) ( Table 4) . During LCx occlusion, posterior myocardial dyskinesis of a similar extent developed in all groups of dogs. In groups 1, 3, and 4, posterior systolic wall thickening remained depressed throughout the 4-hour reperfusion period (Fig 4, Table 4 ). In contrast, in dogs receiving ramiprilat (group 2), posterior systolic wall thickening recovered to 9.8±3.9% (P<.05 versus group 1) at 4 hours of reperfusion (Fig 4, Table 4 ).
By linear regression analysis, a significant correlation between posterior systolic wall thickening and time existed only in group 2 (y-2.8Qv-3.17, r=.710, P<.001). This regression was significantly different from those in groups 1 (y=-0.04x- (Table 6) .
End-diastolic left ventricular pressure increased during LCx occlusion but returned to baseline values upon reperfusion. Thereafter, end-diastolic left ventricular pressure remained constant during the remaining reperfusion period, and there were no significant differences between the respective groups of dogs (Tables 5 and 6 ).
Regional Myocardial Blood Flow
Anterior myocardial blood flow remained constant throughout the experimental protocol within each group of dogs and was not different between groups 5 and 6 (Table 7) and groups 7 and 8 (Table 8) .
During control conditions, posterior myocardial blood flow was not different between groups 5 and 6 (Table 7) and groups 7 and 8 ( Table 8) . Posterior myocardial blood flow did not change in response to administration of indomethacin (group 5) or L-NAME (group 7) . During LCx occlusion, posterior myocardial blood flow was reduced to the same extent in the respective groups of dogs (Tables 7 and 8 ). At 4 hours of reperfusion, posterior myocardial blood flow was somewhat lower than during preischemic control conditions in all groups of dogs but was not different between groups 5 and 6 (Table 7) and groups 7 and 8 (Table 8) .
Regional Myocardial Function
Anterior systolic wall thickening did not change significantly throughout the experimental protocol within each group of dogs and was not different between groups 5 and 6 ( Table 9 ) and groups 7 and 8 (Table 10) . During control conditions, posterior systolic wall thickening was not different between groups 5 and 6 ( Table 9 ) and groups 7 and 8 (Table 10) . Posterior systolic wall thickening decreased slightly in response to indomethacin or L-NAME. This slight decrease, however, was similar in groups 5 and 6 ( Fig 5, Table 9 ) and groups 7 and 8 ( Fig 5, Table 10 ). During LCx occlusion, posterior myocardial dyskinesis of a similar extent developed in all groups of dogs. Posterior systolic wall thickening remained depressed throughout the 4-hour reperfusion period in groups 5, 6, and 7 (Fig 5, Tables 9  and 10 ). In contrast, in dogs receiving ramiprilat in combination with L-NAME (group 8), posterior systolic 1696±574  1858±582  1621±204 1571+175   1489±297 1470±137 1396±109 1414±117 1462±97  1513±262 1490±230 1463+242 1407±236 1435±201 1519±444 1442±368 1462±291   99±9  103±9  101±13  101±13  102±12  104±11   102±10  102+7  100±7  96±12  101±7  103±8  101±9  97+13  100±8  102±7  103±10  100±12  103±13  101±11  100+11  102±12  102±11  101±12  98±10  97±15  100±19 
Discussion
Major Findings
Ramiprilat given before myocardial ischemia improved the functional recovery of stunned myocardium. This beneficial effect of ramiprilat was not related to favorable alterations in systemic hemodynamics or regional myocardial blood flow during ischemia and reperfusion but rather was mediated through a signal cascade of bradykinin and prostaglandins but not nitric oxide.
Methodological Considerations
The present study using a protocol of 15 minutes of coronary occlusion followed by 4 hours of reperfusion was performed in a model of fully reversible ischemia/ reperfusion damage. There was, however, no recovery of function during 4 hours of reperfusion, with the exception of dogs receiving ramiprilat alone (group 2) or in combination with L-NAME (group 8). Persistence of severe dysfunction and lack of recovery during the first few hours of reperfusion have previously been found in a number of studies.15,27-32 The relatively high incidence of ventricular fibrillation in the present study was not responsible for the lack of functional recovery, since anterior (control) wall function and systemic hemodynamics remained fairly stable and recovery in dogs of group 2 with a low incidence of ventricular fibrillation (1 of 8) was similar to those of group 8 with a relatively high incidence of ventricular fibrillation (4 of 6). Finally, In the present study, both indomethacin and L-NAME increased mean aortic pressure and calculated coronary vascular resistance. The somewhat decreased anterior and posterior systolic wall thickening after indomethacin and L-NAME could be a result of increased afterload or, in the case of indomethacin, could be related to an interference with intracellular calcium movements. 42 Certainly, the decreased systolic (Tables 5 and 6 ) and decreases in systolic wall thickening (Tables 9 and 10) (Tables 2 and 6 ). Also, an increase in myocardial blood flow during ischemia and reperfusion cannot explain this beneficial effect of ramiprilat, since ischemic myocardial blood flow in groups 1 through 4 (Table 3 ) and groups 7 and 8 ( trandolapril, enalapril, and ramipril.43 Regional myocardial blood flow during reperfusion was also not changed by enalaprilat in another study using anesthetized dogs.8 Therefore, the beneficial effect of ramiprilat must be related to a direct cardioprotective action.
Mediation of the Beneficial Effect of Ramiprilat Through Bradykinin
The beneficial effect of ramiprilat on the functional recovery of stunned myocardium was prevented by the bradykinin B2 receptor antagonist HOE 140 and thus was obviously mediated through bradykinin. This result is in accordance with previous studies, in which HOE 140 prevented the beneficial effect of ramiprilat on ventricular function during reperfusion after 15 minutes of no-flow ischemia in isolated, buffer-perfused rat hearts. 4, 5 Myocardial ischemia results in an increase of plasma kinin levels in coronary venous blood.44'45 Such increase in coronary venous plasma kinin levels may be the result of both increased formation and reduced breakdown, since plasma pH is reduced under conditions of myocardial ischemia to levels that can result in the activation of plasma kallikrein and a reduction of kinin breakdown.46 ACE is responsible not only for the conversion of angiotensin I to angiotensin II but also for the degradation of bradykinin to inactive metabolites.10 Thus, it is conceivable that ACE inhibitors further reduce bradykinin breakdown. Indeed, an increased bradykinin concentration was measured in the venous effluent of isolated, buffer-perfused rat hearts after administration of ramiprilat. 47 The results of the present study suggest that the basal bradykinin levels during ischemia/reperfusion are insufficient to exert a cardioprotective effect, since the bradykinin B2 receptor antagonist HOE 140 alone had no effect on the functional recovery of stunned myocardium. Thus, only the combination of ramiprilat and ischemia-reperfusion appears to provoke bradykinin formation sufficient to elicit cardioprotection.
At present, the cellular origin of bradykinin during ischemia is unclear, although results from a previous study suggest that endothelial cells contain kininogen48 and release bradykinin after ACE inhibition.'4 However, an additional release of bradykinin from cardiomyocytes cannot be excluded, since a tissue kallikrein has recently been identified in the sarcoplasmic reticulum of rat atrial cardiomyocytes. 49 Whereas the cellular origin of bradykinin and the quantitative contribution of increased formation and reduced degradation during ischemia/reperfusion remain unclear, bradykinin is definitely involved in the cardioprotective action of ramiprilat.
Mediation of the Beneficial Effect of Ramiprilat Through Prostaglandins
Activation of bradykinin B2 receptors in cultured bovine514 and human'4 endothelial cells has been demonstrated to stimulate the formation of prostacyclin as well as nitric oxide, as measured by an enhanced formation of 6-keto-prostaglandin F,a and cGMP. In the same experimental model, a similar increase of the formation of prostacyclin and nitric oxide was induced by ramiprilat5,14 and prevented by the bradykinin B2 receptor antagonist HOE 140. Thus, stimulation of both the prostaglandin and nitric oxide pathways could po- hours of reperfusion when probably some of the beneficial effects of enalaprilat had already occurred.
Prostaglandin synthesis may be stimulated by myocardial ischemia/reperfusion as such,50 although the available data are few and inconsistent. In isolated, bufferperfused rabbit hearts, prostacyclin release did not increase during 2 hours of low-flow ischemia but increased significantly on reperfusion and remained elevated during the remaining 70 minutes of reperfusion. 51 In contrast, the prostacyclin concentration in local coronary venous blood of anesthetized dogs was inester. Group 7, L-NAME; group 8, creased during 30 minutes of coronary occlusion.52 Prostaglandin E2 and F2a concentrations were also increased in the local coronary venous blood during 30 minutes53 or 60 minutes54 of coronary occlusion in anesthetized dogs. In the former study,53 the concentrations of both prostaglandins in the local coronary venous blood increased between 10 and 30 minutes of coronary occlusion, whereas in the latter study such increase was observed already after 1 minute of coronary occlusion.54 Data on reperfusion are available only after the release of a 3-minute coronary occlusion in LCx indicates left circumflex coronary artery; L-NAME, NG-nitro-L-arginine methyl ester. Group 7, L-NAME; group 8, L-NAME+ramiprilat. Data are mean±SD, n=6 per group, P<.05, *vs preceding value, tvs occlusion, *vs group 7. continue to be formed for up to 3 hours of reperfusion after only 15 minutes of myocardial ischemia.68 Lesser damage through reduced free radical formation will nevertheless require repair processes before myocardial function can actually recover. In that sense, recovery of myocardial function may lag behind the immediate cardioprotective action of ramiprilat in the present study. Thus, the detailed mechanism underlying the beneficial effect of prostaglandins on stunned myocardium will have to be elucidated in further studies. Certainly, however, ramiprilat in the present study exerted its beneficial effect on the functional recovery of stunned myocardium through prostaglandins.
Mediation of the Beneficial Effect of Ramiprilat Through Nitric Oxide
Ramiprilat has been demonstrated to increase the formation of nitric oxide in cultured bovine514 and human14 endothelial cells. This effect was prevented by the bradykinin B2 receptor antagonist HOE 140.5.14 A beneficial effect of nitric oxide in the setting of ischemia/ reperfusion is expected from results of a previous study performed in isolated, buffer-perfused rat hearts, in which the administration of a stable nitric oxide radical scavenged oxygen-derived free radicals and protected against reperfusion-induced arrhythmias.19 Indeed, in two previous studies in isolated, buffer-perfused rat5
and guinea pig20 hearts, the beneficial effect of ramiprilat and bradykinin on ventricular function during reperfusion was completely abolished by the nitric oxide synthase inhibitor L-NNA. In contrast, in the present study, inhibition of the nitric oxide synthase by L-NAME did not prevent the ramiprilat-induced improvement in the recovery of stunned myocardium. The reasons for these discrepant findings are unclear, but they are probably related to the different impact of oxygen-derived free radicals in the buffer-perfused heart in vitro versus the blood-perfused heart in vivo, as outlined above. The nitric oxide radical itself is readily scavenged in blood,69 and it is therefore not surprising that in a blood-perfused in vivo heart the role of nitric oxide is less prominent than in a buffer-perfused heart in vitro.
Limitations of the Present Study
The major limitation of the present study is the lack of measurement of bradykinin, prostaglandins, and nitric oxide levels, which was not possible for technical reasons. Furthermore, we realize that even measurement of these mediators in regional coronary venous blood would not have adequately reflected their concentration at the site of action, which is particularly important in autacoids, and thus would not have permitted establishment of a cause-and-effect relation. 4 hours of reperfusion (top). In contrast, in the dogs that received ramiprilat in combination with NG-nitro-Larginine methyl ester (L-NAME), posterior systolic wall thickening recovered significantly more than in dogs that received L-NAME alone (bottom). Data are mean±SD. Therefore, the evidence for the attenuation of myocardial stunning by ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide is indirect in the present study. Also, without adequate measurement of the respective autacoids, it remains unclear when the beneficial effect of ramiprilat occurred. In analogy to a previous study analyzing the effects of the calcium antagonist nisoldipine on myocardial stunning,33 ramiprilat was administered before myocardial ischemia to maximize its potential beneficial effect. We can therefore not distinguish whether ramiprilat induced a preischemic release of bradykinin and prostaglandins that then preconditioned the heart, whether ramiprilat acted during myocardial ischemia, or whether administration of ramiprilat during reperfusion alone would have been equally beneficial. We can, however, conclude that the combination of ramiprilat and ischemia/reperfusion exerted a cardioprotective effect.
Clinical Implications
The beneficial effects of captopril70 and ramipri71 on the long-term prognosis of patients after an acute myocardial infarction have been clearly demonstrated. The AIRE study on ramipril,71 in contrast to the SAVE study on captopril,70 revealed a beneficial effect even within the first 30 days of treatment. In the presence of myocardial infarction, there is in most cases a mixture of irreversibly and reversibly injured myocardium,72 and the improved outcome in patients treated with ramipril in the AIRE study might therefore be related to an enhanced recovery of the reversibly injured myocardium, as demonstrated in the present study. In the AIRE study,71 there was also a trend to a greater benefit from ramipril in patients not receiving aspirin, again supporting the data of the present study that prostaglandins are involved in the beneficial effects of ramiprilat.
In conclusion, ramiprilat in the present study attenuated myocardial stunning through a signal cascade of bradykinin and prostaglandins but not nitric oxide.
